Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan-Reference-Cited by-同舟云学术

Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan

Published:2015-10-20 Issue:2 Volume:63 Page:248-254
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Taga Takashi¹,Watanabe Tomoyuki²,Tomizawa Daisuke³,Kudo Kazuko⁴,Terui Kiminori⁵,Moritake Hiroshi⁶,Kinoshita Akitoshi⁷,MD Shotaro Iwamoto⁸,MD Hideki Nakayama⁹,MD Hiroyuki Takahashi¹⁰,MD Akira Shimada¹¹,Taki Tomohiko¹²,Toki Tsutomu⁵,Ito Etsuro⁵,Goto Hiroaki¹³,Koh Katsuyoshi¹⁴,Saito Akiko M.¹⁵,Horibe Keizo¹⁶,Nakahata Tatsutoshi¹⁷,Tawa Akio¹⁸,Adachi Souichi¹⁹

Affiliation:

1. Department of Pediatrics; Shiga University of Medical Science; Otsu Japan

2. Department of Nutritional Science; Faculty of Psychological and Physical Science; Aichi Gakuin University; Nisshin Japan

3. Division of Leukemia and Lymphoma; Children's Cancer Center; National Center for Child Health and Development; Tokyo Japan

4. Department of Pediatrics; Fujita Health University; Toyoake Japan

5. Department of Pediatrics; Hirosaki University Graduate School of Medicine; Hirosaki Japan

6. Division of Pediatrics; Department of Reproductive and Developmental Medicine; Faculty of Medicine; University of Miyazaki; Miyazaki Japan

7. Department of Pediatrics; St. Marianna University School of Medicine; Kawasaki Japan

8. Department of Pediatrics; Mie University Graduate School of Medicine; Tsu Japan

9. Department of Pediatrics; National Hospital Organization; Fukuoka-Higashi Medical Center; Fukuoka Japan

10. Department of Pediatrics; Toho University; Tokyo Japan

11. Department of Pediatrics; Okayama University Hospital; Okayama Japan

12. Department of Molecular Diagnostics and Therapeutics; Kyoto Prefectural University of Medicine; Kyoto Japan

13. Division of Hemato-Oncology and Regenerative Medicine; Kanagawa Children's Medical Center; Yokohama Japan

14. Department of Hematology/Oncology; Saitama Children's Medical Center; Saitama Japan

15. Laboratory of Clinical; Epidemiological and Health Services Research, Clinical Research Center, National Hospital Organization; Nagoya Medical Center; Aichi Japan

16. Clinical Research Center; National Hospital Organization Nagoya Medical Center; Nagoya Japan

17. Center for iPS Cell Research and Application; Kyoto University; Kyoto Japan

18. Department of Pediatrics; National Hospital Organization; Osaka Medical Center; Osaka Japan

19. Human Health Sciences; Kyoto University; Kyoto Japan

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference17 articles.

1. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity;Creutzig;Leukemia,2005

2. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: Data from 56 children treated on NOPHO-AML protocols and review of the literature;Abildgaard;Ann Haematol,2006

3. Treatment for myeloid leukaemia of Down syndrome: Population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials;Rao;Br J Haematol,2006